The mitochondria-targeted sulfide delivery molecule attenuates drugs-induced gastropathy. Involvement of heme oxygenase pathway.
Gastric mucosa
Heme oxygenase
Hydrogen sulfide
Mitochondria
Non-steroidal anti-inflammatory drugs
Journal
Redox biology
ISSN: 2213-2317
Titre abrégé: Redox Biol
Pays: Netherlands
ID NLM: 101605639
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
14
07
2023
revised:
07
08
2023
accepted:
11
08
2023
medline:
13
9
2023
pubmed:
20
8
2023
entrez:
19
8
2023
Statut:
ppublish
Résumé
Hydrogen sulfide (H
Identifiants
pubmed: 37597422
pii: S2213-2317(23)00248-3
doi: 10.1016/j.redox.2023.102847
pmc: PMC10458696
pii:
doi:
Substances chimiques
Heme Oxygenase (Decyclizing)
EC 1.14.14.18
Sulfides
0
Anti-Inflammatory Agents, Non-Steroidal
0
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102847Subventions
Organisme : Medical Research Council
ID : MR/M022706/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S002626/1
Pays : United Kingdom
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest These authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Matthew Whiteman reports a relationship with MitoRx Therapeutics that includes: equity or stocks. Roberta Torregrossa reports a relationship with MitoRx Therapeutics that includes: employment. Matthew Whiteman has patents awarded and pending for the use of sulfide-delivery molecules.